SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-21-001320
Filing Date
2021-02-09
Accepted
2021-02-08 19:54:18
Documents
4
Period of Report
2020-12-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT gtbp_8k.htm 8-K 34259
2 AMENDMENT TO CONVERTIBLE NOTE gtbp_ex101.htm EX-10.1 13036
3 FORM OF SECURITIES PURCHASE AGREEMENT gtbp_ex102.htm EX-10.2 308899
4 FORM OF DECEMBER 2020 / JANUARY 2021 NOTE gtbp_ex103.htm EX-10.3 166240
  Complete submission text file 0001654954-21-001320.txt   524005
Mailing Address 9350 WILSHIRE BLVD. SUITE 203 BEVERLY HILLS CA 90212
Business Address 9350 WILSHIRE BLVD. SUITE 203 BEVERLY HILLS CA 90212 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

IRS No.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40023 | Film No.: 21603220
SIC: 2834 Pharmaceutical Preparations